» Articles » PMID: 12200546

Trojan Particles: Large Porous Carriers of Nanoparticles for Drug Delivery

Overview
Specialty Science
Date 2002 Aug 30
PMID 12200546
Citations 87
Authors
Affiliations
Soon will be listed here.
Abstract

We have combined the drug release and delivery potential of nanoparticle (NP) systems with the ease of flow, processing, and aerosolization potential of large porous particle (LPP) systems by spray drying solutions of polymeric and nonpolymeric NPs into extremely thin-walled macroscale structures. These hybrid LPPs exhibit much better flow and aerosolization properties than the NPs; yet, unlike the LPPs, which dissolve in physiological conditions to produce molecular constituents, the hybrid LPPs dissolve to produce NPs, with the drug release and delivery advantages associated with NP delivery systems. Formation of the large porous NP (LPNP) aggregates occurs via a spray-drying process that ensures the drying time of the sprayed droplet is sufficiently shorter than the characteristic time for redistribution of NPs by diffusion within the drying droplet, implying a local Peclet number much greater than unity. Additional control over LPNPs physical characteristics is achieved by adding other components to the spray-dried solutions, including sugars, lipids, polymers, and proteins. The ability to produce LPNPs appears to be largely independent of molecular component type as well as the size or chemical nature of the NPs.

Citing Articles

Studies of the Crystallization and Dissolution of Individual Suspended Sodium Chloride Aerosol Particles.

Armstrong Green N, Haddrell A, Gregson F, Lewis D, Church T, Reid J J Phys Chem A. 2024; 128(21):4315-4323.

PMID: 38770785 PMC: 11145642. DOI: 10.1021/acs.jpca.4c02158.


Poly(malic acid)-budesonide nanoconjugates embedded in microparticles for lung administration.

Tessier B, Moine L, Peramo A, Tsapis N, Fattal E Drug Deliv Transl Res. 2024; 14(8):2062-2078.

PMID: 38517568 DOI: 10.1007/s13346-024-01571-4.


Aspherical, Nano-Structured Drug Delivery System with Tunable Release and Clearance for Pulmonary Applications.

Pioch T, Fischer T, Schneider M Pharmaceutics. 2024; 16(2).

PMID: 38399290 PMC: 10891959. DOI: 10.3390/pharmaceutics16020232.


Nano-Formulations for Pulmonary Delivery: Past, Present, and Future Perspectives.

Peng S, Wang W, Zhang R, Wu C, Pan X, Huang Z Pharmaceutics. 2024; 16(2).

PMID: 38399222 PMC: 10893528. DOI: 10.3390/pharmaceutics16020161.


Development of novel polymer haemoglobin based particles as an antioxidant, antibacterial and an oxygen carrier agents.

Majid M, Ullah H, Alshehri A, Tabassum R, Aleem A, Khan A Sci Rep. 2024; 14(1):3031.

PMID: 38321082 PMC: 10847508. DOI: 10.1038/s41598-024-53548-5.


References
1.
Oberdorster G . Pulmonary effects of inhaled ultrafine particles. Int Arch Occup Environ Health. 2001; 74(1):1-8. DOI: 10.1007/s004200000185. View

2.
Kabbaj M, Phillips N . Anticancer activity of mycobacterial DNA: effect of formulation as chitosan nanoparticles. J Drug Target. 2002; 9(5):317-28. DOI: 10.3109/10611860108998768. View

3.
Stroock A, Dertinger S, Ajdari A, Mezic I, Stone H, Whitesides G . Chaotic mixer for microchannels. Science. 2002; 295(5555):647-51. DOI: 10.1126/science.1066238. View

4.
KRENIS L, Strauss B . Effect of size and concentration of latex particles on respiration of human blood leucocytes. Proc Soc Exp Biol Med. 1961; 107:748-50. DOI: 10.3181/00379727-107-26743. View

5.
Kawaguchi H, Koiwai N, Ohtsuka Y, Miyamoto M, SASAKAWA S . Phagocytosis of latex particles by leucocytes. I. Dependence of phagocytosis on the size and surface potential of particles. Biomaterials. 1986; 7(1):61-6. DOI: 10.1016/0142-9612(86)90091-8. View